REGENERON Aktie

>REGENERON Aktienkurs

551.4 EUR +1.9% (TradegateBSX)

Ask: 551.7 EUR / 11 Stück

Bid: 550.6 EUR / 11 Stück

Tagesumsatz: 117 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

REGENERON Aktie über LYNX handeln

Intraday

1 Jahr

>REGENERON Performance

1 Woche: +4,6%

1 Monat: -8,3%

3 Monate: -16,4%

6 Monate: -11,0%

1 Jahr: +30,4%

laufendes Jahr: -16,9%

>REGENERON Aktie

Name:

REGENERON PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US75886F1075 / 881535

Symbol/ Ticker:

RGO (Frankfurt) / REGN (NASDAQ)

Kürzel:

FRA:RGO, ETR:RGO, RGO:GR, NASDAQ:REGN

Index:

S&P500, Nasdaq100

Webseite:

https://www.regeneron.com..

Profil:

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio in..
>Volltext..

Marktkapitalisierung:

56317.72 Mio. EUR

Unternehmenswert:

51035.85 Mio. EUR

Umsatz:

12948.63 Mio. EUR

EBITDA:

3803.8 Mio. EUR

Nettogewinn:

3839.04 Mio. EUR

Gewinn je Aktie:

36.91 EUR

Schulden:

2348.69 Mio. EUR

Liquide Mittel:

2578.16 Mio. EUR

Operativer Cashflow:

Bargeldquote:

1.72

Umsatzwachstum:

-0.82%

Gewinnwachstum:

-7.94%

Dividende je Aktie:

3.12 EUR

Dividendenrendite:

0.59%

Dividendenschätzung:

0.61%

Div. Historie:

20.05.26 - 0.808306€
20.02.26 - 0.798906€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

REGENERON

Letzte Datenerhebung:

06.06.26

>REGENERON Kennzahlen

Aktien/ Unternehmen:

Aktien: 103.02 Mio. St.

Frei handelbar: 97.94%

Leerverk. Aktien: 2.7%

Rückkaufquote: 3.78%

Mitarbeiter: 15410

Umsatz/Mitarb.: 0.81 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 33.77%

Bewertung:

KGV: 15.18

KGV lG: 13.47

KUV: 4.5

KBV: 2.08

PEG-Ratio: 3.4

EV/EBITDA: 13.42

Rentabilität:

Bruttomarge: 80.93%

Gewinnmarge: 29.65%

Operative Marge: 25.76%

Managementeffizenz:

Gesamtkaprendite: 11.28%

Eigenkaprendite: 14.55%

>REGENERON Peer Group

Gesundheit, Antikörper- Behandlung, Augenmedizin/ Sehhilfen, Rheuma- Behandlung, Medizinprodukte & -technik/ Implantate/ Wundpflege
>Alle Branchen..

>REGENERON Chart & Kurs - NASDAQ

>REGENERON News

04.06.26 - 21:15	REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics (Zacks)
	Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion....

04.06.26 - 16:24	Regeneron backed Parabilis seeks up to $476M in U.S. IPO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.06.26 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN (PR Newswire)
	NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.......

04.06.26 - 12:00	Regeneron and CytomX extend cancer therapy partnership to $4bn deal (PBR)
	The collaboration combines CytomX's Probody technology with Regeneron's Veloci‑Bi bispecific platform to target hard‑to‑treat tumour types. Established in 2022, the partnership combines CytomX's biologic masking technology with Regeneron's The post Regeneron and CytomX extend cancer therapy partnership to $4bn deal appeared first on Pharmaceutical Business review....

03.06.26 - 18:12	CytomX-Aktie im Aufwind nach erweiterter Forschungskooperation mit Regeneron (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.06.26 - 15:57	CytomX gains as licensing deal with Regeneron expands (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.06.26 - 15:42	CytomX-Aktie legt nach erweiterter Regeneron-Kooperation und Millionenzahlung zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.06.26 - 14:03	CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer (GlobeNewswire EN)
	- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms -...

02.06.26 - 16:45	Are Options Traders Betting on a Big Move in Regeneron Stock? (Zacks)
	Investors need to pay close attention to REGN stock based on the movements in the options market lately....

01.06.26 - 18:15	Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised) (Zacks)
	REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies....

01.06.26 - 18:15	Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised) (Zacks)
	Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

28.05.26 - 23:21	Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.05.26 - 22:03	Regeneron′s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak (GlobeNewswire EN)
	Inmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients...

27.05.26 - 13:03	ixlayer Appoints Helmut Osorio as General Manager to Accelerate Direct-to-Patient Growth for Biopharma (PR Newswire)
	Former Regeneron, Pfizer and Purdue Pharma commercial leader brings deep expertise as ixlayer expands its award-winning direct-to-patient platform SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- ixlayer, a cloud-based platform powering end-to-end direct-to-patient (DTP) healthcare, today......

26.05.26 - 14:24	Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink? (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

22.05.26 - 14:36	Regeneron Pharmaceuticals′s Genetic Hearing Loss Drug Wins EMA Filing Acceptance (AFX)
	WASHINGTON (dpa-AFX) - Friday, Regeneron Pharmaceuticals, Inc. (REGN) announced that Otarmeni has been accepted by European Medicines Agency for review under Accelerated Assessment the Marketing A......

22.05.26 - 13:03

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss (GlobeNewswire EN)

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA. If approved, Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union (EU)....

22.05.26 - 08:18	Regeneron Reports Positive Results For Lynozyfic In AL Amyloidosis Trial (AFX)
	WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) said its Phase 1/2 LINKER-AL2 trial showed encouraging results for Lynozyfic in patients with relapsed or refractory systemic amyloid li......

22.05.26 - 00:42	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN (PR Newswire)
	NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.......

21.05.26 - 01:24	$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today (Benzinga)
	Importance Rank: 1 read more...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Man möchte wirklich sagen: Die Menschen sind die Teufel auf Erden und die Tiere die geplagten Seelen. - Arthur Schopenhauer

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram